Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study

被引：0
|
作者：
Baldacci, Simon [1 ]
Mazieres, Julien [2 ]
Tomasini, Pascale [3 ]
Girard, Nicolas [4 ]
Guisier, Florian [5 ]
Valette, Clarisse Audigier [6 ]
Monnet, Isabelle [7 ]
Wislez, Marie [8 ]
Perol, Maurice [9 ]
Do, Pascal [10 ]
Dansin, Eric [11 ]
Leduc, Charlotte [12 ]
Leprieur, Etienne Giroux [13 ]
Moro-Sibilot, Denis [14 ]
Kherrouche, Zoulika [15 ]
Labreuche, Julien [16 ]
Cortot, Alexis [1 ]
机构：
[1] Univ Lille, CHU Lille, Serv Pneumol & Oncol Thorac, Lille, France
[2] Toulouse Univ Hosp, Toulouse, France
[3] AP HM, Dept Multidisciplinary Oncol & Therapeut Innovat, Marseille, France
[4] Hosp Civils Lyon, Louis Pradel Hosp, Resp Med, Lyon, France
[5] Rouen Univ Hosp, Rouen, France
[6] Ctr Hosp St Musse, Toulon, France
[7] Ctr Hosp Intercommunal Creteil, Creteil, France
[8] Hop Tenon, Serv Pneumol, AP HP, Paris, France
[9] Ctr Leon Berard, Grp Thorac & Orl, Lyon, France
[10] Ctr Reg Lutte Contre Le Canc Francois Baclesse, Caen, France
[11] Ctr Oscar Lambret, Lille, France
[12] CHU Strasbourg, Strasbourg, France
[13] Hop Ambroise Pare, AP HP, Boulogne, France
[14] Pole Thorax & Vaisseaux, Unite Oncol Thorac, Serv Pneumol, Grenoble, France
[15] Univ Lille, CNRS, Inst Pasteur Lille, Inst Biol Lille,Umr 8161, Lille, France
[16] Univ Lille, Ea 2694, Lille, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
MET amplification; non-small cell lung cancer; EGFR mutation; TKI resistance;
D O I：
10.1016/j.jtho.2016.11.1718
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b-051
引用
收藏
页码：S1219 / S1220
页数：2
相关论文
共 50 条
  • [41] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wenxian Wang
    Hong Wang
    Peihua Lu
    Zongyang Yu
    Chunwei Xu
    Wu Zhuang
    Zhengbo Song
    Journal of Translational Medicine, 17
  • [42] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wang, Wenxian
    Wang, Hong
    Lu, Peihua
    Yu, Zongyang
    Xu, Chunwei
    Zhuang, Wu
    Song, Zhengbo
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [43] Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis
    Ma, Ji-Yong
    Yan, Hai-Jun
    Gu, Wei
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (02) : 397 - 402
  • [44] A retrospective analysis of locally advanced EGFR-mutated NSCLC patients with durvalumab after chemoradiotherapy
    Uchida, Yoshiyasu
    Ninomiya, Takashi
    Harada, Daijiro
    Kozuki, Toshiyuki
    ANNALS OF ONCOLOGY, 2022, 33 : S488 - S488
  • [45] The clinical utility of longitudinal measurement of mutated EGFR in plasma of advanced NSCLC patients during EGFR-TKI treatment
    Szpechcinski, A.
    Bryl, M.
    Wojda, E.
    Czyzewicz, G.
    Swiniuch, D.
    Szwiec, M.
    Ramlau, R.
    Sliwinski, P.
    Barinow-Wojewodzki, A.
    Chorostowska-Wynimko, J.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [46] Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC
    Gammelgaard, Kristine Raaby
    Vad-Nielsen, Johan
    Clement, Michelle Simone
    Weiss, Simone
    Daugaard, Tina Fuglsang
    Dagnws-Hansen, Frederik
    Meldgaard, Peter
    Sorensen, Boe Sandahl
    Nielsen, Anders Lade
    TRANSLATIONAL ONCOLOGY, 2019, 12 (03): : 432 - 440
  • [47] Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
    Oh, Seung Yeon
    Lee, You Won
    Lee, Eun Ji
    Kim, Jae Hwan
    Park, YoungJoon
    Heo, Seong Gu
    Yu, Mi Ra
    Hong, Min Hee
    DaSilva, John
    Daly, Christopher
    Cho, Byoung Chul
    Lim, Sun Min
    Yun, Mi Ran
    CLINICAL CANCER RESEARCH, 2023, 29 (01) : 221 - 232
  • [48] The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
    Lu, S.
    Wang, Q.
    Zhang, G.
    Dong, X.
    Yang, C.
    Song, Y.
    Chang, G.
    Lu, Y.
    Pan, H.
    Chiu, C.
    Wang, Z.
    Feng, J.
    Zhou, J.
    Xu, X.
    Guo, R.
    Chen, J.
    Yang, H.
    Chen, Y.
    Yu, Z.
    Shiah, H.
    Wang, C.
    Yang, N.
    Fang, J.
    Wang, P.
    Wang, K.
    Hu, Y.
    He, J.
    Wang, Z.
    Shi, J.
    Chen, S.
    Cheng, Y.
    Su, W.
    Hsia, T.
    Cui, J.
    Sun, Y.
    Yang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S208 - S209
  • [49] TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC
    Canale, M.
    Ludovini, V.
    Crino, L.
    Dazzi, C.
    Chiadini, E.
    Capelli, L.
    Papi, M.
    Mariotti, M.
    De Luigi, N.
    Minuti, G.
    Calistri, D.
    Baglivo, S.
    Chiari, R.
    Bonafe, M.
    Delmonte, A.
    Ulivi, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S591 - S591
  • [50] First-line concomitant EGFR-TKI plus chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials
    Landre, Thierry
    Assie, Jean-Baptiste
    Chouahnia, Kader
    Des Guetz, Gaetan
    Auliac, Jean-Bernard
    Chouaid, Christos
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 775 - 780
12345